Duration of Therapy: Clinical Trials

16 trials of Duration of Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 terminated, 1 unknown, 1 withdrawn. 16 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 216Completed 13, Terminated 1, Unknown 1, Withdrawn 1

Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days - Community Acquired Pneumonia
Phase 2UnknownEnanta Pharmaceuticals, Inc2502005-12-012006-09-19
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks - Primary Insomnia
Phase 2CompletedH. Lundbeck A/S5202005-11-012015-01-14
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia
Phase 2TerminatedH. Lundbeck A/S502005-11-012015-01-14
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months - B-cell Lymphoma
Phase 2CompletedMerck Sharp & Dohme LLC182005-05-012017-04-07
MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)
Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks - Hypercholesterolemia
Phase 2CompletedMerck Sharp & Dohme LLC4072005-04-012017-04-07
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months - Cutaneous T-cell Lymphoma, Sezary Syndrome
Phase 2CompletedMerck Sharp & Dohme LLC742005-02-032017-04-05
Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)
MK0476, Montelukast Sodium /Duration of Treatment : 14 Days - Bronchiolitis
Phase 2CompletedOrganon and Co122004-12-012024-08-15
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
MK0663, etoricoxib / Duration of Treatment: 4 weeks - Bone Neoplasms
Phase 2WithdrawnOrganon and Co2004-11-012022-02-16
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing
Phase 2CompletedMerck Sharp & Dohme LLC1542004-08-012015-08-25
Endpoint Validation Study (0524A-015)
MK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks - Flushing
Phase 2CompletedMerck Sharp & Dohme LLC1652004-08-012017-02-17
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)
MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks, Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks - Type 2 Diabetes Mellitus
Phase 2CompletedMerck Sharp & Dohme LLC1262004-06-012017-04-04
Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)
MK0812 / Duration of Treatment: 12 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks - Arthritis, Rheumatoid
Phase 2CompletedMerck Sharp & Dohme LLC1492004-06-012015-10-20
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
MK0476, montelukast sodium / Duration of Treatment: 2 Weeks, Comparator: placebo / Duration of Treatment: 2 Weeks - Rhinitis Allergic
Phase 2CompletedOrganon and Co9452004-02-012024-08-15
A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks - Diabetes Mellitus, Type II
Phase 2CompletedMerck Sharp & Dohme LLC7432003-05-132017-03-28
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
MK0826, ertapenem sodium /Duration of Treatment: 14 Days, Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days - Urinary Tract Infections, Bacterial Pneumonia
Phase 2CompletedMerck Sharp & Dohme LLC4002002-01-012017-02-17
A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks, Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks - HIV Infections
Phase 2CompletedMerck Sharp & Dohme LLC3302001-01-012017-02-17

Conditions studied

Diabetes Mellitus, Type 2 (2)  ·  Flushing (2)  ·  Sleep Initiation and Maintenance Disorders (2)  ·  Arthritis, Rheumatoid (1)  ·  Bone Neoplasms (1)  ·  Bronchiolitis (1)  ·  Community-Acquired Pneumonia (1)  ·  HIV Infections (1)  ·  Hypercholesterolemia (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Pneumonia, Bacterial (1)  ·  Rhinitis, Allergic, Perennial (1)

Sponsors

Merck Sharp & Dohme LLC (10)  ·  Organon and Co (3)  ·  H. Lundbeck A/S (2)  ·  Enanta Pharmaceuticals, Inc (1)

Countries

United States (1)

Results publications

PMID 17392721, PMID 18566548, PMID 18946234, PMID 25633134